Mr. Da LIU’s first traditional Chinese book,《生命科技投資啟示錄 - 捕捉下一隻獨角獸》was launched in November 2021. It was awarded with Hong Kong Publishing Biennial Awards 2023 in June 2023. His English publication, “Life Sciences Unicorns – From a China Investment Perspective” was launched in June 2023. This is the first in Hong Kong that systematically explores China’s life sciences investment from a global perspective.

Mr. Liu is one of the founding Managing Directors of CR-CP Life Science Fund, where he spearheaded a number of successful investments in the life science industry, including Legend Biotech (LEGN.US), New Horizon Health (06606.HK), JW Therapeutics (02126.HK), Sirnaomics (02257.HK), Transcenta (06628.HK) and MiRXES.

Mr. Da Liu is dedicated in contributing to the life sciences ecosystem of Hong Kong and the Greater Bay Area: he serves as an advisor to the Committee on Innovation, Technology and Industry Development under the Innovation, Technology and Industry Bureau of Hong Kong SAR Government.